Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xuanyunning is a proprietary traditional Chinese medicine (TCM) developed and manufactured by Guilin Sanjin Pharmaceutical. It is primarily indicated for the treatment of vertigo and dizziness, particularly those arising from TCM patterns such as liver-yang hyperactivity or phlegm-dampness obstruction. The formulation is a complex herbal combination typically including *Gastrodiae Rhizoma* (Tianma), *Uncariae Ramulus Cum Uncis* (Gouteng), *Margaritifera Concha* (Zhenzhu Mu), and other botanical ingredients. These components are traditionally believed to work synergistically to "calm the liver," "extinguish wind," and "resolve dampness." Clinically, it is used to manage symptoms associated with Meniere's disease, hypertension-related dizziness, and vestibular dysfunction. It is marketed in China in oral dosage forms, including tablets and granules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xuanyunning.